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Abstract 
The present study compared knowledge of withdrawal and treatment services 
among 12 primary heroin injectors (PHIs) and 14 primary amphetamine injectors (PAIs). 
Assessment of knowledge about withdrawal and treatment was made using the 
Withdrawal Knowledge Questionnaire (WKQ). Results showed that, on average, 
knowledge about withdrawal differed depending on the drug used. Specifically, regular 
amphetamine users knew less about withdrawal from amphetamine, than regular heroin 
users knew about withdrawal from heroin. In addition, amphetamine users appeared to 
underestimate the likely length of amphetamine withdrawal. There was no difference 
between regular amphetamine and regular heroin users' knowledge of available 
treatment services, such that both groups knew where to seek assistance for 
detoxification and rehabilitation. However, both user groups shared some important 
misconceptions about withdrawal, suggesting a clear need for improved dissemination 
of educational resources among inner metropolitan intravenous drug users, emphasizing 
the length and severity of amphetamine withdrawal and the risks associated with 
excessive self-medication of withdrawal symptoms. 
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Comparing primary heroin and amphetamine injectors’ knowledge of withdrawal and 
treatment options in inner metropolitan Brisbane, Australia. 
 
 
Amphetamines and heroin are the two most commonly injected illicit drugs in Australia 
(Australian Institute of Health and Welfare (AIHW), 1998; McAllister & Makkai, 2001).  
However, a significantly smaller proportion of amphetamine users utilise treatment 
services compared to the proportion of heroin users in Australia (Darke, Kelaher, Hall, 
& Flaherty, 1996; McAllister, 2001; Webster, Mattick, & Baillie, 1992).  This trend 
suggests a need to investigate why amphetamine users are not seeking treatment at the 
same rate as heroin users. 
A number of studies have investigated factors that may underlie the lower rate of 
treatment seeking among amphetamine users compared to heroin users (Hando, Topp, 
& Hall, 1997; Klee & Morris, 1994; Robson & Bruce, 1997; Vincent, Shoobridge, Ask, 
Allsop, & Ali, 1999; Wright & Klee, 1999; Writght, Klee, & Reid, 1999).  These 
studies suggest there are two important factors in this regard: first, amphetamine users 
beliefs about their drug use (e.g. Hando, 1996; Klee, 1998; McElrath & McEvoy, 2001; 
Wright & Klee, 1999; Wright et al., 1999) and second, perceptions about the ability of 
drug-treatment facilities to deal with amphetamine-related problems (Hando et al., 
1997; Vincent et al., 1999; Wright & Klee, 1999; Wright et al., 1999).   
The first factor thought to contribute to lower rates of treatment-seeking by 
amphetamine users compared to heroin users is users’ beliefs about the substances they 
use.  For example, the literature suggests that amphetamines may be perceived as not as 
harmful or addictive as heroin, and that these beliefs may be partly due to stereotypes 
associated with use of these substances (Klee, 1998; McElrath & McEvoy, 2001).  For 
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example, amphetamines (and amphetamine analogues such as “ecstasy” (MDMA)) may 
be perceived as relatively “soft” drugs (e.g., part of youth culture or the dance-music 
scene; recreational; energy-giving), whereas heroin may be perceived as a “hard” drug 
(e.g., more likely to be associated with crime, neglect of self-care or general health 
problems; see Klee, 1998).  Thus, the stereotypes associated with amphetamines and 
heroin may partly account for amphetamine users’ lower rate of treatment seeking than 
heroin users’, particularly if they perceive their drug use as under their control   
In support of the suggestion that amphetamine users may perceive their drug use 
as under their control, research on perceptions of the likelihood of achieving abstinence 
from amphetamine users suggests that amphetamine users may underestimate the 
difficulty of detoxification.  For example, previous research has shown that twice as 
many treatment-seeking amphetamine users rate achieving abstinence as “very hard” as 
non-treatment-seeking amphetamine users (Wright & Klee, 1999).  This difference 
suggests that amphetamine users who have never sought to control their use of 
amphetamines (to the point of abstinence) may be ill prepared for treatment when they 
seek it (e.g., they may have unrealistic expectations).  Further research is also clearly 
needed to examine the reasons for this difference (e.g., which aspects of detoxification 
are perceived differently by in- and out-of-treatment users), as this remains unclear.  
The second factor thought to contribute to lower rates of treatment-seeking by 
amphetamine users compared to heroin users, is beliefs about treatment facilities’ 
abilities to deal with amphetamine dependence specifically.  That is, treatment services 
may be seen as primarily for those experiencing dependence upon “hard” drugs such as 
heroin or those who are not “in control” of their drug use.  Amphetamine users have 
been shown to believe that treatment facilities are unable to deal adequately with the 
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complexities of amphetamine dependence (Hando et al., 1997; Vincent et al., 1999; 
Wright & Klee, 1999; Wright et al., 1999).  
If, as proposed above, the differential rates of treatment-seeking behaviour 
among heroin and amphetamine users can be partly accounted for by differences in 
beliefs (and stereotypes) about heroin and amphetamine use, it may be possible to 
demonstrate this by exploring both groups’ knowledge of the detoxification process 
associated with their drug of choice.  That is, if amphetamine users seek treatment at a 
lower rate than heroin users because they underestimate the complexities of 
amphetamine dependence (they believe their use of amphetamines to be relatively easy 
to control, for example), it should be possible to show differences in level of 
understanding of the withdrawal process associated with each drug by users of that 
substance.  Further, if amphetamine users’ treatment-seeking behaviour is negatively 
impacted by perceptions about the lack of availability or appropriateness of treatment 
facilities for them relative to heroin users, this could be explored by assessing users of 
each substance’s knowledge of treatment services. 
Two specific hypotheses were formulated for this study.  First, it was expected 
that knowledge of withdrawal would differ depending on the drug used such that 
primary amphetamine injectors (PAIs) would know less about amphetamine withdrawal 
than primary heroin injectors (PHIs) would know about heroin withdrawal.  Second, it 
was expected that knowledge of available treatment options would differ depending on 
the drug used, and that PAIs would know less than PHIs about the treatment options 
available for detoxification and rehabilitation. 
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Method 
Participants 
Participants were 26 clients of the Needle Syringe Program (NSP) at the 
Queensland Intravenous and AIDS Association (QuIVAA) situated in inner 
metropolitan Brisbane, Australia. The sample comprised 12 PHIs and 14 PAIs. The 
mean age of the sample was 28.12 years (SD = 10.38; range = 18 - 57) and 21 
participants were male (81%). All participants volunteered and were reimbursed with 
confectionary for their participation.  
The majority of both primary heroin (91%) and PAIs  (71%) were male and 
single. More than half of all participants were unemployed and living with one or more 
other drug users. Although both groups had been using their preferred drug for similar 
periods of time, PHIs were more dependent on their primary drug than PAIs.  This 
finding is consistent with previous studies comparing primary heroin and PAIs’ mean 
SDS scores (Darke & Hall, 1995; Darke, Kaye, & Ross, 1999). In addition, PHIs 
reported higher levels of anxiety than PAIs. 
 
Materials 
Three self-report measures were utilised in the present study. Two of these were 
standardised measures: the Severity of Dependence Scale (SDS) (Gossop et al., 1995) 
and the General Health Questionnaire (GHQ-28) (Goldberg & Williams, 1988). The 
third, the WKQ, was devised for the present study and was comprised of two subscales. 
The first subscale of the WKQ was the Withdrawal Knowledge Scale (WKS). This 
subscale consisted of 24 multiple-choice items each with five-alternatives. The WKS 
was designed to provide a measure of participants’ knowledge of withdrawal. Three 
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items also assessed respondents’ knowledge of the relative severity of withdrawal 
associated with different drugs, including heroin and amphetamines. WKS items were 
based on Turning Point’s (Melbourne, Australia) “Getting Through Amphetamine 
Withdrawal” (Lintzeris et al., 1996a) and “Getting Through Heroin Withdrawal” 
(Lintzeris et al., 1996b) booklets. 
The second subscale of the WKS was the Knowledge of Treatment Options 
Scales (KTOS). The KTOS measured participants’ knowledge of available treatment 
options, in this case those available to users of either drug in Brisbane, Australia. The 
KTOS comprised two further subscales, Knowledge of Detoxification Options (KDO) 
and Knowledge of Rehabilitation Options (KRO), with each subscale containing 10 
true/false items. 
Two versions of the WKQ were created: an amphetamine-version and a heroin-
version. Versions of the WKQ given to primary heroin or PAIs differed only in 
terminology, such that the terms “speed” and “heroin” were interchanged. In all other 
respects, both groups were presented with the same questions and options for response. 
For some items, correct answers varied depending on the primary-substance used. For 
instance, as presented in Figure 1, ‘B’ is the correct answer for this question on the 
heroin version of the WKS, whereas ‘C’ is the correct answer for this question on the 
amphetamine version.   
 
Insert Figure 1 about here. 
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The total score for the WKQ was calculated by summing responses to individual 
items (1 = correct, 0 = incorrect). Copies of the WKQ are available from the 
corresponding author on request. 
 
Procedure 
Recruitment took place from 16 August to 28 September 2001. Clients of the 
NSP were approached for recruitment when collecting their injecting equipment.  
Eligible participants were 18 years of age or older and had to have injected heroin or 
amphetamines at least once in the previous six months. Completion of the 
questionnaires took between 15 and 40 minutes. When assigning participants to groups 
according to their primary drug, poly-drug users who were on the methadone 
maintenance program were assigned to the heroin group.  
 
Results 
Sample Characteristics 
Results are discussed in three sections. First data on substance use and general 
health of participants is presented.  Second, results for the WKS, KDO and KRO based 
on total scores are shown. Finally, to gain further insight into the nature of gaps in 
withdrawal knowledge, an error analysis of WKS items was undertaken.  
Independent samples t-tests showed that primary heroin injector’s mean SDS 
scores were significantly higher than PAIs’ (see Table 2). That is, PHIs were 
significantly more heroin-dependent than amphetamine injectors were amphetamine-
dependent.  However, PAIs’ SDS scores approximated the threshold of ‘five’, on 
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average, representing problematic amphetamine use (Topp & Mattick, 1997). Hence, 
both groups were considered dependent on their primary drug.   
Analysis of mean GHQ total scores suggests both groups were generally 
experiencing similar levels of physical and psychological health (see Table 1). That is, 
there were no significant differences between primary heroin and PAIs’ mean subscale 
totals with respect to ‘somatic symptoms’, ‘social dysfunction’ or ‘severe depression’. 
There was one exception to this general trend: that is, PHIs scored significantly higher 
than PAIs on the ‘anxiety’ subscale of the GHQ. 
 
Insert Table 1 about here. 
 
PHIs were more experienced with respect to past episodes of withdrawal and 
seeking information about withdrawal than PAIs. All PHIs (100%) had previously 
experienced withdrawal at least once, compared to 79% of PAIs. In addition, 92% of 
PHIs had previously sought information on withdrawal compared to PAIs (65%). 
However, a similar percentage of primary heroin (58%) and primary amphetamine 
(50%) injectors had had previous assistance with detoxification from a treatment centre. 
 
Analyses of Total Scores on the WKS, KRO and KDO 
The data consisted of the total number of correct responses made by each 
participant on the WKS, KDO and KRO. Independent groups t-tests were conducted to 
explore significant differences between the mean number of correct responses made by 
primary heroin and PAIs on these three scales. As presented in Table 2, PHIs scored 
significantly higher on the WKS than PAIs. This suggests that PHIs knew more about 
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heroin withdrawal than PAIs knew about amphetamine withdrawal. However, no 
significant differences were found between primary heroin and PAIs’ mean total scores 
on the KDO or KRO. This suggests both groups were equally knowledgeable about 
treatment options for detoxification and rehabilitation. 
 
Insert Table 2 about here. 
 
Error Analysis of Individual Items on the WKS 
Error analysis of the WKQ was undertaken to identify if there were patterns of 
errors made by the two groups that would suggest participants were either over- or 
under-estimating withdrawal. Items selected for error analysis were defined as those 
items answered correctly by less than 50% of the sample.   
There were three items for which the majority of participants from each group 
responded incorrectly (items 1, 14 and 24). These items related to the length of 
withdrawal from heroin or amphetamines, the relative length of withdrawal for a variety 
of substances, and the role of medications in alleviating withdrawal symptoms. The 
pattern of errors in both groups was similar such that both groups: first, underestimated 
the length of withdrawal from their preferred drug (71% of PAIs thought amphetamine 
withdrawal takes 4 to 5 days, while 50% of PHIs estimated heroin withdrawal takes no 
more than 6 to 10 days) (item 1); second, chose an option suggesting they thought 
medications could stop withdrawal symptoms rather than provide temporary relief (item 
14), and; third, underestimated the length of amphetamine withdrawal relative to other 
substances (50% of amphetamine users and 58% of heroin users thought withdrawal 
lasted longest for heroin rather than amphetamines, the latter being the correct answer 
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for this item) (item 24). Hence, both groups underestimated the length of withdrawal 
from their preferred drug and the severity of amphetamine withdrawal, and 
overestimated the effectiveness of medication in alleviating withdrawal symptoms.  
Finally, more than 50% of PHIs also made errors on three additional items. First, 
errors by  PHIs  in this sample suggest they may overestimate when cravings can be 
expected to dissipate (50% of heroin users overrated the length of time cravings were 
likely to persist) (item 7). Second, two items dealt with the persistent of cravings and 
the potential need for inpatient support for heroin relative to amphetamines and other 
drugs. Primary heroin injectors’ responses on these items suggest that this group may 
underestimate the extent and severity of amphetamine withdrawal. PHIs.  Hence, PHIs 
underestimated the severity of amphetamine withdrawal and overestimated the 
persistence of cravings with heroin withdrawal. Overall, both groups underestimated the 
length and severity of amphetamine withdrawal and shared the belief that medication 
can stop withdrawal symptoms altogether.  
Discussion 
The present study examined primary heroin and PAIs’ knowledge of withdrawal 
processes and treatment options related to these substances. It was expected that PAIs 
would know less than PHIs about both their potential withdrawal process and their 
available treatment options. Consistent with expectations, the results of independent 
groups t-tests showed that PAIs were significantly less knowledgeable than PHIs with 
respect to withdrawal as measured on the WKS. However, contrary to expectations 
there was no significant difference between primary heroin and PAIs’ knowledge of 
treatment services available to them. Both groups were equally aware of appropriate 
detoxification and rehabilitation services.  
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These outcomes may be attributable to differences between each group’s 
withdrawal experience. Around a fifth of PAIs (21%) reported that they had never 
previously experienced amphetamine withdrawal, despite the fact that both groups had 
been using their preferred drug for similar periods of time. Likewise, 36% of PAIs had 
never previously sought information on withdrawal, compared to 8% of PHIs. Hence, 
PHIs were more likely than PAIs to have been able to draw from both personal accounts 
of withdrawal and educational resources when responding to WKS items. This finding 
is consistent with previous research (to the extent that heroin users are more likely to 
seek treatment than amphetamine users (e.g., McAllister, 2001)), however it may also 
partly account for PHIs higher WKS scores compared to PAIs.  
Another important interpretative caveat on the generalisability of results from 
this study relates to the nature of the sample used. The characteristics of the present 
sample suggest it was representative of amphetamine and heroin injecting samples 
described in previous research that have been drawn from a wide-variety of settings 
(Darke & Hall, 1995; Darke, Kaye & Ross, 1999; Kaye & Darke, 2000). However, the 
generalisability of these findings may be limited to intravenous drug users (IDUs) from 
inner urban districts. That is, participants in this study were mostly male, in their late 
twenties, single, living with one or more other drug users, and had been using for 
approximately ten years. The extent to which the results of the present study generalise 
to intravenous drug users drawn from other settings is an empirical question that merits 
further research. 
Despite these caveats, the results of the present study provide some insight into 
the nature of misconceptions IDUs may have about withdrawal. As such, these findings 
may inform the development of relevant educational resources. For example, error 
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analysis highlighted three factors relating to withdrawal that may require particular 
emphasis in drug education programs. First, participants’ patterns of errors on the WKS 
showed that a high percentage of both groups underestimated the length and severity of 
amphetamine withdrawal. In particular, PAIs tended to underestimate the length of 
amphetamine withdrawal by at least two weeks. Further, education interventions for 
both heroin and amphetamine injectors may need to emphasise more strongly the 
potential return of moderate-to-severe cravings and nervous agitation in the third to 
fourth week of amphetamine withdrawal. These recommendations have added 
significance when considering that PHIs are increasingly injecting amphetamines when 
there is a reduced supply of heroin (McAllister, 2001).  
Second, error analysis suggested that PHIs may overestimate the length of time 
cravings persist with heroin withdrawal. Half of the present sample of PHIs 
overestimated the length of time cravings are likely to continue before dissipating by at 
least one week. Hence, educational interventions reinforcing that cravings during heroin 
withdrawal may not last as long as users’ expect may be important to establish realistic 
expectations, particularly among those contemplating or attempting heroin withdrawal. 
Finally, error analysis indicated primary heroin and amphetamine injectors 
might be unaware of risks associated with excessive use of medication throughout 
withdrawal. Specifically, IDUs in this sample reported believing that medication can 
stop withdrawal symptoms (rather than temporarily reduce symptoms). They did not 
demonstrate an appreciation of the addictive nature of medications such as 
benzodiazepines that are used for this purpose. These findings are consistent with 
previous studies showing high levels benzodiazepine misuse among both heroin and 
amphetamine users (Darke, 1994; Darke & Hall, 1995; Darke & Ross, 1997), especially 
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when undergoing self-detoxification (Gossop, Battersby & Strang, 1991). Educational 
interventions may therefore need to highlight more strongly risks associated with 
excessive self-medication during heroin or amphetamine withdrawal.   
Altering educational resources in the manner outlined above may be especially 
important for amphetamine users who until now have not sought treatment to the same 
extent as heroin users. Knowing what to expect is a key ingredient to successfully 
completing detoxification (Lintzeris et al., 1996a, 1996b). It may be particularly 
important to ensure that such information is emphasised to amphetamine users given the 
beliefs they may have about their drug use, particularly the ease with which they believe 
abstinence may be achieved.  
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Panel A: Heroin Version 
 
Heroin withdrawal symptoms generally peak (are 
worst) after: 
A. the first day 
B. 2 to 4 days 
C. 5 to 10 days 
D. 11 to 14 days 
E. 15 to 28 days 
 
 
      Panel B: Amphetamine Version 
 
Speed withdrawal symptoms generally peak (are 
worst) after: 
A. the first day 
B. 2 to 4 days 
C. 5 to 10 days 
D. 11 to 14 days 
E. 15 to 28 days 
 
 
 
Figure 1. An Item From the Version of the WKS Given to PHIs (Panel A) and the Version Given to PAIs (Panel B). The Correct Answer For Each 
Version Of This Item Is Shown (Circled). 
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Table 1. PHIs’ and PAIs’ drug-use history, severity of dependence (as measured on the SDS), and health and psychological functioning as 
measured on the GHQ-28 (N = 26). 
Variable 
PHIsPHIsPHIsPHIsPH
IsPHIsPHIsPHIsPHIs
PAIs  t values* 
Observed 
Power 
 M SD M SD   
Age Primary-Drug First Used (Years) 19.67 5.23 16.07 4.89 3.28, ns .41 
Age Primary-Drug First Injected (Years) 19.58 5.23 17.29 5.47  1.19, ns .18 
Years Primary-Drug Used 10.25 7.63 10.5 7.88  .01, ns .05 
Severity of Dependence** 7.92 2.84 4.86 2.8  7.62, p<.05 .75 
Somatic Symptoms 7.25 1.96 5.8 2.87 2.19, ns .3 
Anxiety/Insomnia 8.67 4.19 5.34 3.56 4.75, p<.05 .55 
Social Dysfunction 5.71 3.38 7.08 2.65 1.33, ns .2 
Severe Depression 3.75 3.17 3.19 4.68 .12, ns .06 
GHQ Total 25.38 5.99 21.54 9.6 1.44, ns .21 
* df = 25; the alpha level used to determine significance = .05.  **SDS score. 
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Table 2. PHIs’ and PAIs’ mean scores on the WKS, KDO and KRO (N = 26). 
Variable 
PHIsPHIsPHIsPHIsPHIs
PHIsPHIsPHIsPHIs 
PAIs  t scores* 
Observed 
Power 
 M SD M SD   
WKS (total) 12.25 2.45 9.14 3.39 6.93, p<.05 .71 
KDO  (total) 5.75 2.67 4.29 2.43 2.14, ns  .29 
KRO (total) 4.42 3.18 3.57 2.17 .64, ns .12 
*df = 25; the alpha level used to determine significance = .05. 
 
 
 
